An Essential Review of Hepatocellular Carcinoma: Advances in Clinical Understandings

Supported by an educational grant from Bayer & Exelixis, Inc. 

TITLE - An Essential Review of Hepatocellular Carcinoma: Advances in Clinical Understandings

TARGET AUDIENCE - Target audiences for this program are Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, Oncology Pharmacists, Oncology Nurses, and Nurses

LEARNING OBJECTIVES - After completing the program, Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, Oncology Pharmacists, Oncology Nurses, and Nurses

  1. Describe the epidemiology and rising incidence of hepatocellular carcinoma (HCC)
  2. Discuss the various etiologies and risk factors associated with the development of HCC
  3. List the symptoms associated with HCC
  4. Identify patients who should be screened for HCC
  5. Describe the importance of early identification of HCC for improved outcomes
  6. Discuss various pharmacologic and nonpharmacologic treatment strategies for patients with HCC and their safety and efficacy
  7. Explain the importance of treatment adherence in HCC patients and major barriers to adherence and compliance

Faculty Disclosures:

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/ services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by the Specialty Pharma Education Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Faculty Disclosure: Lisa E. Davis, PharmD, FCCP, BCPS, BCOP, discloses that she is a speaker for Acurity and a consultant for Novartis Pharmaceuticals Corporation. She does intend to discuss non-FDA approved drugs or investigational use of any product/device. 

Pharmacist continuing education credit

Specialty Pharma Education Center (SPEC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 2.0 hours (0.20CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test (score of 70% or higher). Participants will have 3 opportunities to pass the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
ACPE #0535-0000-20-003-H01-P

Knowledge Based Activity

Course release date 3/2/2020

Course expires 3/2/2023

Nursing continuing education credit

Educational Review Systems is an approved provider of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Provider # 5-115. This program is approved for 2.0 hours of continuing nursing education. 

Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia. 

Course release date: 3/13/2020

Course expires: 3/13/2022

Credit Information

Activity Number Credit Amount Accreditation Period
0535-0000-20-003-H01-P 0.2 CEUs March 02, 2020 - March 02, 2023
0535-0000-20-003-H01-N 2 hours of CNE March 13, 2020 - March 13, 2022